Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of…


-Study to evaluate the safety and efficacy of ATH-1017 to improve mild-to-moderate Alzheimer’s disease-

Read more:
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of...

Related Posts